COVIDCOVID-19NCT04416061
The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic
An observational study of COVID, run by Hong Kong Sanatorium & Hospital at 1 site in Hong Kong.
Trial summary
Hong Kong public healthcare system is facing tremendous pressure under the COVID-19 pandemic. As the virus spread in Hong Kong, Hong Kong Sanatorium \& Hospital (HKSH) is one of the first private hospitals which immediately provide reliable and rapid COVID-19 test -- Reverse Transcription Polymerase Chain Reaction… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COVID
- What is being tested?
- COVID 19 Diagnostic Test
- How many people
- 2,510 participants
- Where
- 1 siteHong Kong
- Study dates
- 11 May 2020to 31 Jul 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Subjects who underwent COVID-19 test in HKSH during the study period
Who may be able to join
- Subjects who underwent COVID-19 test in HKSH during the study period
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic: A Descriptive Study of Patients With SARS-CoV-2 RT-PCR Performed
Hong Kong public healthcare system is facing tremendous pressure under the COVID-19 pandemic. As the virus spread in Hong Kong, Hong Kong Sanatorium \& Hospital (HKSH) is one of the first private hospitals which immediately provide reliable and rapid COVID-19 test -- Reverse Transcription Polymerase Chain Reaction (RT-PCR). Early provision of the RT-PCR screening test for COVID-19 not only facilitates identification of COVID-19 but also contains the spread of the virus in the community and frontline medical staff.
Since description of role of private hospital in Hong Kong amid COVID-19 pandemic is lacking, this study will describe COVID-19 screening algorithm and methodology. A retrospective analysis on clinical characteristics, laboratory findings as well as outcome of patients who underwent COVID-19 test in HKSH is also performed.
- Conditions
- COVID
- Being tested
- COVID 19 Diagnostic Test
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
COVID 19 Diagnostic TestDiagnostic test
COVID 19 Diagnostic Test
| Study group | Role | What they receive |
|---|---|---|
| Subjects underwent COVID-19 test | Subjects who underwent COVID-19 test in HKSH during the study period Receives: Diagnostic Test: COVID 19 Diagnostic Test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of asymptomatic subjects
Proportion of asymptomatic subjects (%) who underwent COVID 19 test
Measured: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Secondary outcomes (2)
Proportion of subjects with recent contact history
Proportion of subjects (%) with recent contact history
Measured: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Proportion of subjects with recent travel history
Proportion of subjects (%) with recent travel history
Measured: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2020
- Study start11 May 2020
- Primary completion31 Jul 2020
- Study completion31 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,510 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hong Kong Sanatorium & Hospital
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Principal investigator, Dr. Jonpaul ST Zee, Hong Kong Sanatorium & Hospital
- Investigators
- Jonpaul Sze Tsing Zee, MBChB, Principal investigator, Hong Kong Sanatorium & Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04416061
- Sponsor's protocol ID
- RC-2020-08
- Acronym
- COVID-19
- Status last verified
- Feb 2024
- First submitted
- 1 Jun 2020
- Last updated
- 28 Feb 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic: A Descriptive Study of Patients With SARS-CoV-2 RT-PCR Performed
- ClinicalTrials.gov ID
- NCT04416061
- Acronym / sponsor ID
- COVID-19 / RC-2020-08
- Conditions
- COVID
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,510 participants (actual)
- Lead sponsor
- Hong Kong Sanatorium & HospitalIndustry (pharma, biotech, devices)
- Study start
- 11 May 2020 (actual)
- Primary completion
- 31 Jul 2020 (actual)
- Study completion
- 31 Jul 2020 (actual)
- First posted
- 4 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hong Kong public healthcare system is facing tremendous pressure under the COVID-19 pandemic. As the virus spread in Hong Kong, Hong Kong Sanatorium \& Hospital (HKSH) is one of the first private hospitals which immediately provide reliable and rapid COVID-19 test -- Reverse Transcription Polymerase Chain Reaction (RT-PCR). Early provision of the RT-PCR screening test for COVID-19 not only facilitates identification of COVID-19 but also contains the spread of the virus in the community and frontline medical staff.
Since description of role of private hospital in Hong Kong amid COVID-19 pandemic is lacking, this study will describe COVID-19 screening algorithm and methodology. A retrospective analysis on clinical characteristics, laboratory findings as well as outcome of patients who underwent COVID-19 test in HKSH is also performed.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Subjects underwent COVID-19 test | – | Diagnostic Test: COVID 19 Diagnostic TestSubjects who underwent COVID-19 test in HKSH during the study period |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Subjects who underwent COVID-19 test in HKSH during the study period
Key inclusion criteria (1 listed)
- Subjects who underwent COVID-19 test in HKSH during the study period
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| COVID 19 Diagnostic TestCOVID 19 Diagnostic Test | Diagnostic test | Subjects underwent COVID-19 test |
Primary outcome
Proportion of asymptomatic subjects
Time frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Proportion of asymptomatic subjects (%) who underwent COVID 19 test
2 secondary outcomes
Proportion of subjects with recent contact history
Time frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Proportion of subjects with recent travel history
Time frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Feb 2024.
- Individual participant dataSharing planned: No
Related trials for COVID
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
RecruitingPhase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Coronavirus Disease (COVID-19)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonpaul Sze Tsing Zee, MBChB principal investigator
Hong Kong Sanatorium & Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID, run by Hong Kong Sanatorium & Hospital at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of asymptomatic subjects (time frame: 1 Feb 2020 until the 14th consecutive day without any local infection in Hong Kong). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024; AzTrials last refreshed its copy on 8 Nov 2026.